Divya Bharat
biology, Biotechnology, brand safety-nsf health issues, brand safety-nsf products and consumers negative, brand safety-nsf sensitive, business, business and industry sectors, children, children's health, Communicable Disease Control, companies, continents and regions, demographic groups, diseases and disorders, domestic alerts, domestic-health and science, domestic-us news, economy and trade, families and children, family members and relatives, GlaxoSmithKline plc, government organizations - us, health and health care (by demographic group), Health and Medical, iab-biological sciences, iab-biotech and biomedical industry, iab-business and finance, iab-children's health, iab-diseases and conditions, iab-family and relationships, iab-healthy living, iab-industries, iab-infectious diseases, iab-lung and respiratory health, iab-medical health, iab-parenting, iab-parenting babies and toddlers, iab-pharmaceutical drugs, iab-pharmaceutical industry, iab-pregnancy, iab-reproductive health, iab-science, iab-vaccines, iab-women's health, infants and toddlers, infectious diseases, international alerts, international-health and science, international-us news, life forms, maternal and child health, medical biotechnology, medical fields and specialties, North America, obstetrics and gynecology, pediatric vaccinations, Pfizer Inc., pharmaceutical industry, pharmaceuticals, pharmaceuticals and prescription drugs, population and demographics, pregnancy and childbirth, Public Health, respiratory diseases, Science, society, the americas, united states, US Department of Health and Human Services, us federal departments and agencies, US Food and Drug Administration, vaccination and immunization, viruses, women's health
Late-stage RSV vaccine trials show ‘exciting promise,’ some scientists say | CNN
CNN  — A Pfizer vaccine to protect older adults and infants from respiratory syncytial virus (RSV) infection has shown what
Read More